CD47 and neoplasm: By blocking CD47-induced inhibitory "don't-eat-me" signaling, ES004-B5 exerts superior antitumor activity in combination with anti-tumor-associated antigen antibodies <i>in vitro</i> and <i>in vivo</i>.